Macrocyclic Lactone Derivatives for Enhanced Bioavailability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Rapamycin's low bioavailability and high immunosuppressive potency, along with its potential toxicity, limit its utility as a pharmaceutical drug, and its low water solubility complicates its therapeutic applications.

Innovation Solution

Development of novel macrocyclic lactones with specific chemical modifications, such as demethylation, hydroxylation, epoxidation, and N-oxidation, which are synthesized chemically or biologically to preserve immunosuppressive and anti-proliferative properties, and their use in pharmaceutical compositions for systemic and site-specific therapeutic applications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If rapamycin is used as a pharmaceutical drug, then immunosuppressive and anti-proliferative therapeutic effects are achieved, but bioavailability is very low and variable

Engineering Contradiction:
Improvetherapeutic efficacyVSAvoidbioavailability
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of rapamycin through demethylation, hydroxylation, epoxidation, and N-oxidation at specific positions. These structural modifications alter the physicochemical properties of the molecule, particularly improving its solubility and bioavailability while preserving the immunosuppressive and anti-proliferative therapeutic effects through maintained binding affinity to mTOR and other target proteins.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If rapamycin is used as a pharmaceutical drug, then immunosuppressive potency is achieved, but toxicity is high

Engineering Contradiction:
Improveimmunosuppressive potencyVSAvoidtoxicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by introducing specific functional groups at particular positions on the rapamycin macrocyclic ring structure. These localized modifications (demethylation at C-4, hydroxylation at C-11 or C-16, epoxidation at C-26/C-27, N-oxidation at C-42) selectively improve solubility and reduce toxicity without compromising the essential pharmacophore regions required for immunosuppressive activity.

Inventive Principle:
Principle #3Local quality

3Reliability

If rapamycin is used as a pharmaceutical drug, then therapeutic effects are achieved, but water solubility is very low

Engineering Contradiction:
Improvetherapeutic efficacyVSAvoidwater solubility
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies parameter changes by introducing polar functional groups (hydroxyl, carboxyl, amino groups) through chemical modifications such as hydroxylation and N-oxidation. These modifications increase the polarity and hydrogen-bonding capacity of the rapamycin derivative molecules, thereby significantly improving their water solubility while maintaining the macrocyclic lactone structure essential for biological activity.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentUS10123996B2Macrocyclic lactone compounds and methods for their use
Publication Date: 2018.11.13 ELIXIR MEDICAL CORP
  • US10123996B2 patent drawing
  • US10123996B2 patent drawing
  • US10123996B2 patent drawing

AI summary

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula:wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2,—O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of:wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of:andsalts, isomers, or N-oxides thereof.